NewAmsterdam Pharma Company N.V., a clinical biopharmaceutical company focused on developing oral, non-statin medicines for cardiovascular disease, announced the approval of inducement share options for eleven new non-executive employees. The grants, totaling 197,000 of NewAmsterdam's ordinary shares, are part of the 2024 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of $20.03, reflecting the closing market price as of May 1, 2025. The vesting schedule includes 25% of the shares vesting on the one-year anniversary of the vesting commencement date, with the remainder vesting over the following 36 months, contingent on continued service with the company.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。